XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues:    
Total revenues $ 1,509,000 $ 3,220,000
Operating expenses (income):    
Cost of revenues 825,000 3,458,000
Research and development 359,000 395,000
Change in fair value of contingent consideration 0 (31,000)
Gain on sale of property and equipment (19,000) (328,000)
Selling, general and administrative 4,392,000 4,349,000
Total operating expenses 5,557,000 7,843,000
Loss from operations (4,048,000) (4,623,000)
Interest income (expense) 198,000 (1,000)
Other income, net 32,000 14,000
Valuation loss on March 2023 PIPE (6,076,000) 0
Change in fair value of common stock warrant and option liabilities 940,000 0
Issuance and offering costs allocated to liability classified options (430,000) 0
Net loss (9,384,000) (4,610,000)
Net loss attributable to non-controlling interest 0 (122,000)
Net loss attributable to common stockholders $ (9,384,000) $ (4,488,000)
Net loss per share attributable to common stockholders:    
Basic net loss per share attributable to common stockholders: $ (10.86) $ (8.09)
Diluted net loss per share attributable to common stockholders: $ (10.86) $ (8.09)
Weighted-average number of shares used in per share calculations:    
Weighted average shares - Basic 864,391 554,675
Weighted average shares - Diluted 864,391 554,675
Product    
Revenues:    
Total revenues $ 1,509,000 $ 3,170,000
Royalty    
Revenues:    
Total revenues $ 0 $ 50,000